Interleukin-21 Influences Glioblastoma Course: Biological Mechanisms and Therapeutic Potential.
cancer immunology
cytokines
glioblastoma
interleukin-21
primary brain tumors
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
received:
10
08
2023
revised:
11
09
2023
accepted:
14
09
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Brain tumors represent a heterogeneous group of neoplasms involving the brain or nearby tissues, affecting populations of all ages with a high incidence worldwide. Among the primary brain tumors, the most aggressive and also the most common is glioblastoma (GB), a type of glioma that falls into the category of IV-grade astrocytoma. GB often leads to death within a few months after diagnosis, even if the patient is treated with available therapies; for this reason, it is important to continue to discover new therapeutic approaches to allow for a better survival rate of these patients. Immunotherapy, today, seems to be one of the most innovative types of treatment, based on the ability of the immune system to counteract various pathologies, including cancer. In this context, interleukin 21 (IL-21), a type I cytokine produced by natural killer (NK) cells and CD4
Identifiants
pubmed: 37759505
pii: cells12182284
doi: 10.3390/cells12182284
pmc: PMC10526836
pii:
doi:
Substances chimiques
interleukin-21
MKM3CA6LT1
Interleukins
0
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2009 Mar 15;15(6):2123-9
pubmed: 19276257
Cancers (Basel). 2014 Mar 25;6(2):663-83
pubmed: 24670367
Blood. 2008 May 1;111(9):4723-30
pubmed: 18182577
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946718
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14028-33
pubmed: 18779574
Mol Ther Oncolytics. 2022 Jun 06;26:105-119
pubmed: 35795092
J Immunother. 2018 Jun;41(5):224-231
pubmed: 29683891
J Rheumatol. 2010 Oct;37(10):2014-20
pubmed: 20682664
Brain Nerve. 2023 May;75(5):561-566
pubmed: 37194532
Trends Immunol. 2015 Oct;36(10):569-577
pubmed: 26431936
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Immunity. 2002 Apr;16(4):559-69
pubmed: 11970879
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4
pubmed: 10841526
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Brain Tumor Res Treat. 2022 Jul;10(3):158-163
pubmed: 35929113
Blood. 1994 Jan 1;83(1):113-8
pubmed: 8274730
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Am Fam Physician. 2016 Feb 1;93(3):211-7
pubmed: 26926614
Immunol Lett. 2016 Jan;169:61-72
pubmed: 26597610
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
J Immunol. 2005 Dec 15;175(12):7867-79
pubmed: 16339522
Am J Cancer Res. 2015 Feb 15;5(3):945-55
pubmed: 26045979
PLoS One. 2012;7(4):e35036
pubmed: 22496888
Med Oncol. 2023 May 30;40(7):191
pubmed: 37249661
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
pubmed: 15977639
Anticancer Res. 2006 Nov-Dec;26(6B):4191-4
pubmed: 17201132
Cancer Cell. 2008 Mar;13(3):206-20
pubmed: 18328425
Science. 2007 Dec 14;318(5857):1744-8
pubmed: 18079394
Blood. 2007 May 15;109(10):4135-42
pubmed: 17234735
Lancet. 2018 Aug 4;392(10145):432-446
pubmed: 30060998
Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Science. 2009 Jun 19;324(5934):1576-80
pubmed: 19478140
Proc Natl Acad Sci U S A. 1989 May;86(10):3803-7
pubmed: 2786204
Cancer Immunol Immunother. 2018 Feb;67(2):237-246
pubmed: 29058035
Front Oncol. 2016 Jan 29;6:16
pubmed: 26858939
Oncotarget. 2017 Aug 16;8(46):80208-80222
pubmed: 29113296
Nat Rev Cancer. 2020 Jan;20(1):12-25
pubmed: 31806885
Cell. 1997 Oct 17;91(2):231-41
pubmed: 9346240
J Immunol. 2004 Jul 1;173(1):657-65
pubmed: 15210829
Gene. 2016 Jan 10;575(2 Pt 1):187-90
pubmed: 26341051
Neuro Oncol. 2016 Feb;18(2):252-60
pubmed: 26289592
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1518-23
pubmed: 19164519
Science. 2002 Nov 22;298(5598):1630-4
pubmed: 12446913
Int J Mol Sci. 2018 Mar 27;19(4):
pubmed: 29584702
J Biol Regul Homeost Agents. 1997 Jul-Sep;11(3):91-103
pubmed: 9498158
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S53-72
pubmed: 19932918
Cancer Immunol Immunother. 2011 Feb;60(2):173-86
pubmed: 20972785
Biochemistry. 2011 May 31;50(21):4804-12
pubmed: 21524095
Br J Pharmacol. 2013 Feb;168(3):591-606
pubmed: 23062197
Cells. 2021 Aug 31;10(9):
pubmed: 34571905
Front Immunol. 2023 Jan 10;13:1009484
pubmed: 36703992
Sci Adv. 2023 Apr 28;9(17):eade2675
pubmed: 37115922
Science. 2010 Nov 5;330(6005):841-5
pubmed: 20966214
Front Pharmacol. 2019 Jun 05;10:506
pubmed: 31231208
Clin Exp Rheumatol. 2013 Mar-Apr;31(2):172-9
pubmed: 23137515
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11439-44
pubmed: 11016959
J Histochem Cytochem. 2007 Jul;55(7):687-700
pubmed: 17341475
Int J Oncol. 2006 Oct;29(4):981-7
pubmed: 16964394
Int J Cancer. 2007 Oct 15;121(8):1756-63
pubmed: 17582604
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4365-70
pubmed: 17360530
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
Hum Gene Ther. 2017 Feb;28(2):200-215
pubmed: 27758144
Nature. 2000 Nov 2;408(6808):57-63
pubmed: 11081504
Brain Sci. 2022 May 31;12(6):
pubmed: 35741603
Pharmacol Ther. 2013 Sep;139(3):313-26
pubmed: 23644076
Nat Rev Immunol. 2009 Jul;9(7):480-90
pubmed: 19543225
Nanomaterials (Basel). 2023 May 12;13(10):
pubmed: 37242036
Handb Clin Neurol. 2022;190:149-161
pubmed: 36055712
Anticancer Res. 2018 Nov;38(11):6041-6045
pubmed: 30396918
EBioMedicine. 2018 Jul;33:49-56
pubmed: 30049387
Cells. 2023 Mar 08;12(6):
pubmed: 36980182
J Neuroinflammation. 2016 Nov 24;13(1):297
pubmed: 27881137
Biomark Insights. 2021 Mar 30;16:11772719211006666
pubmed: 33854293
Trends Cancer. 2017 Feb;3(2):75-78
pubmed: 28718447
Handb Clin Neurol. 2016;134:19-26
pubmed: 26948346
AMA Arch Neurol Psychiatry. 1954 Nov;72(5):568-72
pubmed: 13206476
J Neuroimmunol. 2021 Aug 15;357:577633
pubmed: 34153803
J Immunol. 2004 May 1;172(9):5154-7
pubmed: 15100251
Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):477-84
pubmed: 22885885
Biomed Res Int. 2017;2017:7403747
pubmed: 29259986
Blood. 2002 Dec 15;100(13):4565-73
pubmed: 12393685
Mol Cancer Ther. 2006 Jul;5(7):1817-26
pubmed: 16891468
Acta Pharm Sin B. 2021 Nov;11(11):3465-3480
pubmed: 34900530
Am J Med. 2018 Aug;131(8):874-882
pubmed: 29371158
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Biol Chem. 2000 Dec 22;275(51):40307-15
pubmed: 11007768
Biochem Pharmacol. 2011 Apr 15;81(8):1004-15
pubmed: 21300032
Oncogene. 2016 Nov 10;35(45):5819-5825
pubmed: 27041580
Sci Rep. 2015 Apr 21;5:9956
pubmed: 25898313
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
J Immunol. 2002 May 1;168(9):4772-80
pubmed: 11971028
J Neurosurg. 1992 May;76(5):799-804
pubmed: 1373442
Adv Exp Med Biol. 2012;746:53-76
pubmed: 22639159
J Neuropathol Exp Neurol. 1998 Jul;57(7):653-63
pubmed: 9690669
Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):223-32
pubmed: 17509926
CNS Neurosci Ther. 2012 Aug;18(8):609-15
pubmed: 22686334
J Exp Med. 2005 Jan 3;201(1):139-48
pubmed: 15630141
Curr Oncol Rep. 2021 Feb 25;23(3):35
pubmed: 33630180
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396284
Neuropathology. 2011 Apr;31(2):129-34
pubmed: 20667016
J Immunol. 2001 Jul 1;167(1):1-5
pubmed: 11418623
Oncoimmunology. 2013 Jun 1;2(6):e24522
pubmed: 23894713
Annu Rev Immunol. 2008;26:57-79
pubmed: 17953510
Cytokine. 2022 Jan;149:155749
pubmed: 34739898
Semin Oncol Nurs. 2004 Nov;20(4):260-72
pubmed: 15612602
J Cell Physiol. 2021 Feb;236(2):863-876
pubmed: 32657468
Front Immunol. 2023 Mar 09;14:1123853
pubmed: 36969167
Sci Adv. 2021 Aug 27;7(35):
pubmed: 34452907
Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):301-13
pubmed: 25837897